Amgen announces positive top-line results from Phase 3 GAUSS-2 trial of Evolocumab (AMG 145) in statin intolerant patients with high cholesterol
23 January 2014 | By Amgen
Study meets co-primary endpoints of LDL cholesterol reduction...
List view / Grid view
23 January 2014 | By Amgen
Study meets co-primary endpoints of LDL cholesterol reduction...
19 December 2013 | By Sanofi
Collaboration represents the first time the ACC’s PINNACLE Registry Research Alliance will be used for clinical trial recruitment...
17 December 2013 | By Amgen
Study meets co-primary endpoints of LDL cholesterol reduction...
20 November 2013 | By Amgen
Data presented at American Heart Association Scientific sessions 2013 and simultaneously published in circulation...
14 November 2013 | By Amgen
First long-term data of a PCSK9 Inhibitor to be featured in clinical science: special reports session...
16 October 2013 | By Sanofi
Alirocumab monotherapy reduced “bad” cholesterol three times more than ezetimibe...
5 November 2012 | By
Results from RUTHERFORD study presented at American Heart Association Scientific Sessions 2012...